• Patients ≥ 18 years old and ≤ 65 years old

• Refractory/Relapse AML patients according to 2016 World Health Organization (WHO) classification;

• Eastern Cooperative Oncology Group (ECOG) Performance status score less than 3;

• Liver function: Total bilirubin ≦2 upper limit of normal (ULN); aspartate aminotransferase (AST) ≦3 ULN; alanine aminotransferase (ALT)≦3 ULN

• Renal function：Ccr（Creatinine Clearance Rate） ≧30 ml/min; Scr (serum creatinine) ≦2 ULN

• Heart function: left ventricular ejection fraction ≧45%

• Patients must participate in this clinical trial voluntarily and sign an informed consent form.